VisEn Fluorescence Molecular Tomography (FMT) scanner

描述(由申请人提供)：申请资金购买临床前荧光分子断层成像(FMT)成像系统，以支持H.Lee Moffitt癌症中心与癌症相关的研究。该仪器将被安置在小动物成像实验室SAIL内并进行操作，该实验室位于莫菲特间隔室。Moffitt是美国国立卫生研究院在佛罗里达州唯一指定的综合癌症中心，最近做出了开发世界级临床和临床前癌症成像能力的重大承诺。佛罗里达州没有其他类似的文书。因此，该文书同SAIL内的所有其他文书一样，将作为一种区域资源。6个主要用户和13个次要用户在这项提案上进行了合作，代表了27项由NIH资助的赠款，包括药物发现计划项目、胸部肿瘤学的孢子赠款和物理科学肿瘤学中心的赠款。这些研究人员代表癌症中心内六个研究项目中的五个，包括药物发现、实验治疗学、免疫学、分子肿瘤学和风险评估、检测和干预。这一新的仪器将使目前无法在四个不同的研究领域进行的一些研究成为可能：治疗反应评估、分子图谱、免疫治疗中的细胞跟踪以及抗体/配体/纳米制剂的生物分布。对于治疗反应的评估，可以用肿瘤荧光蛋白表达和一些商用荧光探针的生物活性来监测对实验药物和治疗方案的反应。对于分子图谱，可以使用新的和可用的靶向荧光探针来识别关键的诊断和预后标记的表达。通过过继地将表达荧光蛋白的细胞转移到同种小鼠品系中，并使用多个渠道对表达荧光蛋白的异种移植瘤进行成像共定位，可以监测细胞跟踪。最后，可以对正在开发的新型靶向分子显像剂的结合特异性、生物分布和摄取和清除的药代动力学进行定量评估。 公共卫生相关性：申请资金为H.Lee Moffitt癌症中心购买临床前动物成像仪器，该中心是NCI在佛罗里达州唯一指定的综合癌症中心。这种荧光分子断层成像仪器能够生成内部表达的荧光蛋白、与内脏器官、原位肿瘤模型和生化活动相关的荧光探针的定量测量和高分辨率断层图像。这样的仪器将使研究人员能够监测治疗反应，描述癌症的分子表型，在免疫治疗期间非侵入性跟踪细胞，并跟踪氟铬结合分子在全身的分布。由于佛罗里达州目前没有这种能力，这一工具也将作为其他机构的调查人员的区域资源。

DESCRIPTION (provided by applicant): Funds are requested to purchase a pre-clinical fluorescence molecular tomography (FMT) imaging system to support cancer-related research at the H. Lee Moffitt Cancer Center. This instrument will be housed and operated within the Small Animal Imaging Laboratory, SAIL, situated within the Moffitt vivarium. The Moffitt is the only NIH-designated Comprehensive Cancer Center in the State of Florida, and has recently made a major commitment to developing world class clinical and preclinical cancer imaging capabilities. No other comparable instrument exists in the State of Florida. Thus, this instrument, as all other instruments within SAIL, will be intended to serve as a regional resource. Six major users and 13 minor users have collaborated on this proposal, representing 27 NIH funded grants, including a Program Project in Drug Discovery, a SPORE grant in Thoracic Oncology and a Physical Science Oncology Center grant. These investigators represent five of six research programs within the Cancer Center, including; Drug Discovery, Experimental Therapeutics, Immunology, Molecular Oncology and Risk Assessment, Detection & Intervention. This novel instrumentation will make possible a number of currently inaccessible studies in four distinct areas of research: therapy response assessment, molecular profiling, cell tracking in immunotherapy, and antibody/ligand/nanoagent biodistribution. For therapy response assessment, tumor expression of fluorescent protein expression and the bioactivity of a number of commercially available fluorescent probes can be used to monitor response to experimental drugs and therapeutic regimens. For molecular profiling, novel and available targeted fluorescent probes may be used to identify the expression of key diagnostic and prognostic markers. Cell tracking can be monitored by adoptive transfer of cells engineered to express fluorescent protein into congenic mouse strains and imaging co-localization to fluorescent protein expressing xenograft tumors using multiple channels. Finally, binding specificity, biodistribution and pharmacokinetics of uptake and clearance can be quantitatively assessed for novel targeted molecular imaging agents under development. Public Health Relevance: Funds are requested to purchase a pre-clinical animal imaging instrument for the H. Lee Moffitt Cancer Center, the only NCI designated Comprehensive Cancer Center in the State of Florida. This fluorescence molecular tomography instrument is capable of generating quantitative measurements and high-resolution tomographic images of internally expressed fluorescent proteins, and fluorescent probes associated with internal organs, orthotopic tumor models and biochemical activities. Such an instrument will enable investigators to monitor therapy response, profile molecular phenotypes of cancers, noninvasively track cells during immunotherapy and track the distribution of fluorochrome-conjugated molecules throughout the body. Since this capability is not currently available in the State of Florida, this instrument will serve as a regional resource for investigators at other institutions as well.